Fig. 5
From: Multilayered control of exon acquisition permits the emergence of novel forms of regulatory control
Hematologic cancers display decreased exonization. a Boxplots displaying percentage change in Alu-exonized events compared to matched patient controls. Dots represent data from individual samples. See Fig. 2c for the description of boxplots. SCLC, small cell lung cancer; MDS, myelodysplastic syndromes; CLL, chronic lymphocytic leukemia; AML, acute myeloid leukemia. b Boxplots showing data from a collated into two major cancer types. See Fig. 2c for the description of boxplots. c Boxplots displaying changes in Alu exonization relative to matched control samples in cell lines expressing RNA binding proteins with known cancer mutations. See Fig. 2c for the description of boxplots. d Dot plot displaying changes in Alu exonization of MDS samples grouped by genes containing mutations. Each dot represents data from an individual study. e Dot plot showing the number of exonized events in SET2 cell line samples and patient samples before and after administration of bromodomain inhibitor ARV-825. Independent healthy control samples from the same cell type (CD34+) are also included. ARV-825, BRD4 inhibitor